Method for amelioration of insulin resistance
OwnerJoseph Michael Abramowitzinventor
Life of this patent
Estimating the term…
Abstract
A method is disclosed utilizing the administration of extended release L-tri-iodothyronine in order to ameliorate insulin resistance. In other embodiments extended release L-tri-iodothyronine is combined with a biguanide and/or a thiazolidinedione and/or an inhibitor of the endoplasmic reticulum integrated stress response to provide a multi-targeted and synergistic approach to ameliorate insulin resistance.
Claims15
A method for preventing or treating insulin resistance in the cells of a human patient, the method comprising the steps of:
- a) providing L-tri-iodothyronine in an extended release formulation;
- and b) administering said extended release formulation to a human patient.
A pharmaceutical formulation for preventing or treating insulin resistance in a human patient comprising L-tri-iodothyronine, a biguanide, and a thiazolidinedione
A method for preventing or treating insulin resistance in a human patient, the method comprising the steps of:
- a) providing a drug from the class of endoplasmic reticulum integrated stress response inhibitors in an appropriate formulation;
- and b) administering said formulation to a human patient.
Dependencies are inferred from the claim text.